AstraZeneca was domestically approved for the atomized-type product of its asthma treatment ‘Symbicort’

The new formulation of the AstraZeneca’s asthma treatment, Symbicort, is about to be launched. Its strength is the easier inhalation with the atomized type than the existing products.

According to the Ministry of Food and Drug Safety on the 31^st, AstraZeneca has acquired approvals for the domestic marketing of its 3 volume types, such as Symbicort Rapihaler 40/2.25mcg, 80/2.25mcg and 160/4.5mc...